Shenzhen Hepalink Pharmaceutical Group Co., Ltd. - Laporan Laba Rugi (TTM)

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
HK ˙ SEHK ˙ CNE100003YN2
HK$ 5.93 ↑0.18 (3.13%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Shenzhen Hepalink Pharmaceutical Group Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2022
01-01
2022
03-31
2022
06-30
2022
09-30
2023
01-01
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 5,028 5,332 5,198 5,786 6,421 6,365 7,008 7,010 7,129 7,159 6,550 6,114 5,827 5,431 5,518 5,570 5,451 5,259 5,280 5,239
Change (%) 6.05 -2.52 11.33 10.96 -0.87 10.09 0.04 1.69 0.43 -8.51 -6.66 -4.68 -6.80 1.60 0.95 -2.13 -3.53 0.40 -0.78
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 3,070 3,300 3,363 3,878 4,324 4,367 4,848 4,771 4,847 4,861 4,377 4,075 3,928 4,490 4,553 4,584 4,498 3,520 3,633 3,624
Change (%) 7.49 1.90 15.32 11.50 0.99 11.02 -1.60 1.60 0.30 -9.96 -6.91 -3.62 14.32 1.41 0.68 -1.89 -21.75 3.23 -0.26
% of Revenue 61.06 61.89 64.70 67.02 67.34 68.61 69.19 68.05 67.99 67.90 66.83 66.65 67.40 82.68 82.52 82.30 82.51 66.93 68.81 69.17
Gross Operating Profit 1,958 2,032 1,835 1,908 2,097 1,998 2,159 2,240 2,282 2,298 2,173 2,039 1,900 941 965 986 953 1,739 1,647 1,615
Change (%) 3.78 -9.70 4.00 9.88 -4.70 8.07 3.72 1.90 0.69 -5.45 -6.17 -6.81 -50.48 2.52 2.19 -3.28 82.44 -5.32 -1.92
% of Revenue 38.94 38.11 35.30 32.98 32.66 31.39 30.81 31.95 32.01 32.10 33.17 33.35 32.60 17.32 17.48 17.70 17.49 33.07 31.19 30.83
SG&A 820 832 801 819 834 923 966 987 1,043 1,025 1,073 1,094 1,028 1,193 878 818 843 1,020 1,034 1,027
Change (%) 1.51 -3.79 2.33 1.74 10.67 4.73 2.13 5.69 -1.77 4.76 1.96 -6.06 16.02 -26.39 -6.81 3.09 20.95 1.36 -0.65
% of Revenue 16.31 15.61 15.40 14.16 12.98 14.49 13.79 14.08 14.63 14.31 16.39 17.90 17.64 21.96 15.91 14.69 15.47 19.40 19.58 19.61
R&D 106 160 160 183 200 221 224 242 279 252 258 268 238 191 168 160 5 22
Change (%) 51.31 0.03 14.57 8.82 10.80 1.40 7.92 15.22 -9.55 2.23 4.12 -11.41 -12.08 -4.71 361.31
% of Revenue 2.10 3.00 3.08 3.17 3.11 3.47 3.20 3.45 3.91 3.52 3.94 4.39 4.08 3.47 3.02 2.94 0.09 0.41
OpEx 4,005 4,318 4,348 4,912 5,394 5,532 6,053 6,023 6,179 6,161 5,739 5,466 5,232 5,648 5,648 5,602 5,541 4,513 4,677 4,661
Change (%) 7.83 0.69 12.96 9.83 2.54 9.43 -0.51 2.59 -0.29 -6.85 -4.75 -4.28 7.96 0.00 -0.82 -1.08 -18.56 3.63 -0.33
% of Revenue 79.65 80.99 83.66 84.88 84.01 86.90 86.38 85.91 86.67 86.05 87.61 89.41 89.78 104.00 102.37 100.58 101.65 85.82 88.58 88.98
Operating Income 1,023 1,014 849 875 1,026 834 954 988 950 999 812 647 595 -217 -131 -32 -90 746 603 578
Change (%) -0.92 -16.21 2.98 17.36 -18.80 14.47 3.51 -3.78 5.08 -18.73 -20.21 -8.04 -136.49 -39.87 -75.46 181.17 -927.20 -19.14 -4.22
% of Revenue 20.35 19.01 16.34 15.12 15.99 13.10 13.62 14.09 13.33 13.95 12.39 10.59 10.22 -4.00 -2.37 -0.58 -1.65 14.18 11.42 11.02
Interest Expense -271 -248 -231 -211 -199 -202 -199 -213 -218 -235 -247 -240 -239 -223 -207 -187 -162 -141 -118 -386
Change (%) -8.47 -6.69 -8.89 -5.71 1.55 -1.15 6.78 2.53 7.80 4.83 -2.64 -0.38 -6.67 -7.33 -9.79 -13.41 -12.62 -16.07 225.73
% of Revenue -5.38 -4.65 -4.45 -3.64 -3.09 -3.17 -2.84 -3.04 -3.06 -3.29 -3.77 -3.93 -4.10 -4.11 -3.75 -3.35 -2.96 -2.68 -2.24 -7.37
Net Income 1,097 1,024 912 781 777 241 332 414 432 727 559 340 218 -783 -695 -243 -146 647 648 405
Change (%) -6.61 -10.92 -14.37 -0.54 -69.02 37.98 24.54 4.29 68.57 -23.15 -39.24 -35.71 -458.74 -11.30 -65.03 -39.77 -542.02 0.24 -37.54
% of Revenue 21.81 19.21 17.55 13.50 12.10 3.78 4.74 5.90 6.05 10.16 8.53 5.56 3.75 -14.42 -12.59 -4.36 -2.68 12.30 12.28 7.73

Source: Capital IQ

Other Listings
US:SHEZF
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista